May 20, 2014
Update on Availability of EGRIFTATM in the United States
Montreal, Canada – May 20, 2014 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will be releasing additional limited supplies of the 2 mg/vial presentation of EGRIFTATM (tesamorelin for injection) in the early part of June. This comes as a result of on-going communications with the FDA and a Company determination that there is a critical need to maintain the supply for existing patient use. This will allow the Company to help patients stay on therapy during the production stoppage.
“This is welcome news for patients who might have had to interrupt treatment for a few weeks due to the product shortage that was caused by the production stoppage,” said Luc Tanguay, President and CEO, Theratechnologies Inc.